RELORN Trademark

Trademark Overview

On Wednesday, February 8, 2023, a trademark application was filed for RELORN with the United States Patent and Trademark Office. The USPTO has given the RELORN trademark a serial number of 97786502. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Monday, September 23, 2024. This trademark is owned by Unipharm, Inc.. The RELORN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for pain relief and fever reduction
relorn

General Information

Serial Number97786502
Word MarkRELORN
Filing DateWednesday, February 8, 2023
Status731 - SECOND EXTENSION - GRANTED
Status DateMonday, September 23, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 1, 2023

Trademark Statements

Goods and ServicesPharmaceuticals for pain relief and fever reduction

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 17, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameUnipharm, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10118
Party NameUnipharm, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10118

Trademark Events

Event DateEvent Description
Saturday, February 11, 2023NEW APPLICATION ENTERED
Friday, February 17, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 30, 2023ASSIGNED TO EXAMINER
Wednesday, May 31, 2023NON-FINAL ACTION WRITTEN
Wednesday, May 31, 2023NON-FINAL ACTION E-MAILED
Wednesday, May 31, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, June 20, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 20, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 20, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, June 23, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 12, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 1, 2023PUBLISHED FOR OPPOSITION
Tuesday, August 1, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 26, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, March 26, 2024SOU EXTENSION 1 FILED
Monday, April 29, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, April 29, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, April 30, 2024TEAS PETITION TO REVIVE RECEIVED
Tuesday, April 30, 2024NOTICE OF REVIVAL - E-MAILED
Tuesday, April 30, 2024PETITION TO REVIVE-GRANTED
Tuesday, April 30, 2024SOU EXTENSION RECEIVED WITH TEAS PETITION
Tuesday, April 30, 2024TEAS PETITION TO REVIVE RECEIVED
Monday, July 8, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, July 9, 2024SOU EXTENSION 1 GRANTED
Tuesday, July 9, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 23, 2024SOU TEAS EXTENSION RECEIVED
Monday, September 23, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 23, 2024SOU EXTENSION 2 FILED
Monday, September 23, 2024SOU EXTENSION 2 GRANTED

Related Keywords

relorn reduction fever relief pain pharmaceuticals